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Introduction {#sec1}
============

Atherosclerosis is a lipid-driven chronic disease of the artery wall and the underlying cause of heart attacks and strokes, which accounts for the majority of mortalities and morbidities in the world ([@bib33]). It is characterized by chronic inflammatory responses to endogenous sterile triggers, such as oxidized LDL (OxLDL), dying cells, and their metabolic byproducts that trigger tissue inflammation if not efficiently cleared ([@bib46], [@bib24]). Persistence of this inflammatory response or its impaired resolution paves the way for chronic inflammatory responses, which have been shown to propagate associated pathologies such as vascular and hepatic inflammation ([@bib47]). Thus, there is growing interest in identifying mechanisms that enhance the immune system's capacity to prevent endogenously triggered inflammation and/or promote its resolution.

B cells, which can be subdivided into B-1 and B2 cells, are emerging players in the chronic inflammation of metabolic diseases, such as obesity, diabetes, and atherosclerosis ([@bib49], [@bib54], [@bib55], [@bib40]). B2 cells, which include follicular (FO) B cells and marginal zone (MZ) B cells, have been shown to promote atherosclerotic lesion formation in murine models of atherosclerosis via mechanisms that are largely unclear ([@bib30], [@bib1]). On the other hand, selective transfer of B-1 cells, which can be further divided into B-1a and B-1b cells, protects mice from atherosclerosis ([@bib31], [@bib43]). One of the main functions of B-1 cells is the production of natural IgM antibodies (NAb), which are pre-existing germline encoded antibodies that arise without any conventional T cell help and comprise approximately 80% of IgM antibodies in unchallenged mice ([@bib4]). B-1a cells seem to exhibit their atheroprotective effects via the secretion of NAb ([@bib49]). Indeed, atherosclerosis-prone soluble IgM-deficient mice develop accelerated atherosclerosis, though the exact mechanism by which NAb protect is not entirely clear ([@bib32]). We and others have suggested that NAb promote the neutralization and clearance of self-antigens, such as dying cells and oxidized lipids ([@bib48]). These studies indicate the importance of selective regulation of individual B cell subsets for appropriate responses to inflammatory triggers. Moreover, the role of B-1 cells in atherosclerosis has only been studied in immune-compromised animals, and their role in animals that do not lack major compartments of the immune system remains elusive. In this regard, the sialic acid-binding immunoglobulin-like lectin G (Siglec-G) is of particular interest as it acts as negative regulator of the B-1a cell population size, presumably via inhibiting B cell receptor dependent signaling ([@bib22], [@bib19]). We and others have previously shown that mice deficient in Siglec-G exhibit a nearly 10-fold expansion of B-1a cells along with a robust increase in total serum IgM ([@bib22], [@bib19]). Moreover, we also found that Siglec-G deficiency results in an expansion of IgM with specificity for oxidation-specific epitopes (OSE), which represent prototypic metabolic byproducts present on OxLDL, dying cells, and circulating microparticles ([@bib18], [@bib50], [@bib13], [@bib14], [@bib28]). As excessive accumulation of OSE has been suggested to be a key driver for inflammatory reactions in metabolic diseases, such as atherosclerosis, non-alcoholic steatohepatitis, and diabetes ([@bib35], [@bib52], [@bib23]), targeting Siglec-G may have beneficial therapeutic effects in chronic inflammation.

The expansion of B-1a cells has also been associated with increased autoimmunity ([@bib12], [@bib39], [@bib27]), which could accelerate atherosclerosis ([@bib42], [@bib34]). Siglec-G deficiency has been shown to result in an earlier onset of autoimmune disease in the Murphy Roths Large/lymphoproliferative (MRL/lpr) lupus mouse model and leads to mild autoimmunity in aging mice with an over-activation of adaptive T and B cells ([@bib36], [@bib10]). In addition, Siglec-G has also been found to be expressed in and influence responses of myeloid cells. For example, Siglec-G has been shown to be upregulated by RNA viruses and to inhibit retinoic acid-inducible gene 1 (RIG-I) mediated IFN-β secretion by macrophages and dendritic cells. In line with this, vesicular stomatitis virus (VSV)-infected Siglec-G-deficient mice were found to display increased IFN-β production and decreased viral load compared to control mice ([@bib17]). Moreover, dendritic cells of Siglec-G-deficient mice have been found to exhibit increased pro-inflammatory cytokine secretion in response to multiple danger-associated molecular patterns (DAMPs) (e.g., HSP70, HSP90, and HMGB1). A detrimental role of Siglec-G deficiency is further supported by the findings that Siglec-G-deficient mice exhibit increased mortality in models of acetaminophen-induced liver necrosis ([@bib15]) and cecal ligation and puncture-induced sepsis ([@bib16]). Thus, all studies so far indicate that Siglec-G functions as negative regulator of inflammation, and Siglec-G deficiency may actually propagate inflammatory responses. Because pro-inflammatory cytokine production is a hallmark of metabolic inflammation, the role of Siglec-G and the consequences of Siglec-G deficiency in chronic inflammation and specifically in atherosclerosis are entirely unknown.

Here, we investigated the role of Siglec-G in sterile chronic inflammation in vivo. We demonstrate that total as well as B cell-specific Siglec-G deficiency reduces atherosclerotic lesion formation as well as hepatic inflammation in hypercholesterolemic *Ldlr*^−*/*−^ mice. Moreover, we show that Siglec-G-deficient mice are protected form OxLDL-induced inflammation in vivo.

Results {#sec2}
=======

Siglec-G Deficiency in Cholesterol-Fed Ldlr^−/−^ Mice Increases B-1a Cells and Natural IgM Antibodies {#sec2.1}
-----------------------------------------------------------------------------------------------------

Siglec-G deficiency has been previously shown to result in an expansion of OSE-specific NAb, which are hypothesized to possess robust anti-inflammatory properties, particularly against products of increased oxidative stress ([@bib28]). In agreement with previous data, non-atherosclerotic *Siglec-G*^−/−^ mice have---compared to *Siglec-G*^+/+^ control mice---significantly increased numbers of B-1a cells in the spleen, increased numbers of CD138^+^ plasmablasts (B220^+^) and plasma cells (B220^lo^) in the spleen and bone marrow, and increased levels of OSE-specific IgM antibodies in the plasma ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1G). In order to investigate the effect of Siglec-G deficiency in atherosclerosis, *Ldlr*^−/−^*Siglec-G*^−/−^ mice as well as control *Ldlr*^−/−^ mice were fed an atherogenic diet for 8 weeks. Siglec-G deficiency did not affect body weight, or plasma total cholesterol (TC), or triglycerides (TG) ([Table 1](#tbl1){ref-type="table"}). Moreover, there was no significant difference in frequencies of total or Ly6C^hi^ and Ly6C^lo^ monocytes in the peripheral blood of these mice ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F). Frequencies of peripheral blood B220^+^ B cells were also not different between the two groups ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

Consistent with the previously described effect of Siglec-G deficiency on B cells, numbers of splenic CD43^+^ B-1 cells were increased in *Ldlr*^−/−^*Siglec-G*^−/−^ mice ([Figures 1](#fig1){ref-type="fig"}A and 1B). Numbers of CD3^+^ T cells, CD23^+^ FO B cells, and MZB cells were not different between the groups ([Table 1](#tbl1){ref-type="table"}). Notably, the numbers of the recently identified pro-atherogenic subset of innate response activator (IRA) B cells in the spleen were significantly increased in *Ldlr*^−/−^*Siglec-G*^−/−^ mice compared to *Ldlr*^−/−^ mice ([@bib21]) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Moreover, compared to *Ldlr*^−/−^ mice, *Ldlr*^−/−^*Siglec-G*^−/−^ mice exhibited a significantly increased frequency of B-1a cells in the peritoneal cavity ([Figures 1](#fig1){ref-type="fig"}C and 1D), while the frequencies of B-1b or B2 cells were not significantly different between the groups ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).

We then assessed both total and OSE-specific IgM and IgG antibody levels in plasma at baseline and after 8 weeks of atherogenic diet. Levels of IgM antibodies were significantly increased in *Ldlr*^−/−^*Siglec-G*^−/−^ mice at both time points ([Figure 1](#fig1){ref-type="fig"}E), while levels of total IgG antibodies were not different ([Figure 1](#fig1){ref-type="fig"}F). Moreover, IgM titers to MDA-LDL as well as to CuOx-LDL were also higher in *Ldlr*^−/−^*Siglec-G*^−/−^ mice at baseline and even further increased in response to atherogenic diet feeding compared to controls ([Figures 1](#fig1){ref-type="fig"}G and 1H). Importantly, expression of the antigen-specific IgM as a ratio of total IgM, revealed a preferential expansion of IgM to MDA-LDL and CuOx-LDL, while the relative levels of IgM to the atherosclerosis-irrelevant antigen α-1,3-dextran were decreased ([Figure 1](#fig1){ref-type="fig"}I). On the other hand, IgG titers to these antigens were elevated in *Ldlr*^−/−^*Siglec-G*^−/−^ mice only at baseline, but the differences disappeared after 8 weeks of atherogenic diet ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Thus, even in the presence of extreme hypercholesterolemia, Siglec-G deficiency results in an expansion of B-1a cells and a concomitant increase of total and OSE-specific IgM.

Total and B Cell-Selective Siglec-G Deficiency Protects from Atherosclerosis {#sec2.2}
----------------------------------------------------------------------------

We then quantified the extent of atherosclerosis in the entire aorta of both groups of mice by *en face* analyses, which revealed a 50% reduced lesion size as a result of Siglec-G deficiency ([Figure 2](#fig2){ref-type="fig"}A). Decreased atherosclerosis was also found in the innominate arteries of *Ldlr*^−/−^*Siglec-G*^−/−^ mice compared to *Ldlr*^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}B). Moreover, while cross-sectional analyses of the aortic origin did not reveal differences in lesion size between the two groups ([Figure 2](#fig2){ref-type="fig"}C), lesions of *Ldlr*^−/−^*Siglec-G*^−/−^ mice were clearly less complex with smaller necrotic areas and reduced macrophage content ([Figures 2](#fig2){ref-type="fig"}D and 2E). Lesional collagen content was not significantly different between the two groups ([Figure 2](#fig2){ref-type="fig"}F), while deposition of IgM was significantly increased in lesions of *Ldlr*^−/−^*Siglec-G*^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}G). Thus, Siglec-G deficiency results in a profound reduction of lesion size and complexity.

To identify whether the observed protective effects of Siglec-G deficiency are mainly conferred by B cells, we generated bone marrow chimeric *Ldlr*^−/−^ mice with a selective Siglec-G deficiency on B cells using a previously established method ([@bib44], [@bib20]). *Ldlr*^−/−^ mice were lethally irradiated and reconstituted with (1) bone marrow from *Siglec-G*^−/−^ mice or *Siglec-G*^*+/+*^ littermate controls to assess the role of Siglec-G deficiency in hematopoietic cells in general, and (2) a mixture of 80% bone marrow from B cell-deficient *μMT* mice and 20% from either *Siglec-G*^−/−^ mice or *Siglec-G*^*+/+*^ littermate controls to assess Siglec-G deficiency specifically in B cells. After a 4 week recovery period, mice were fed an atherogenic diet for 10 weeks. Successful engraftment of the respective bone marrow was confirmed by PCR of DNA isolated from bone marrow of recipients and of sorted splenic B and non-B cells to demonstrate selective Siglec-G deficiency ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). In addition, the lack of Siglec-G expression on splenic B cells was confirmed by flow cytometry ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

Body weights, TC and TG levels in plasma, as well as frequencies of peripheral blood monocytes and B cells were not different between the experimental groups ([Table 2](#tbl2){ref-type="table"}; [Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). Splenic B-1 cells as well as peritoneal B-1a cells were significantly increased in recipients of *Siglec-G*^−/−^ bone marrow (whole and mixed bone marrow) compared to recipients of control bone marrow ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}D; [Table 2](#tbl2){ref-type="table"}). Moreover, total plasma IgM levels were significantly increased in mice reconstituted with *Siglec-G*^−/−^ and μMT+*Siglec-G*^−/−^ bone marrow compared to their controls ([Figure 3](#fig3){ref-type="fig"}B), while total plasma IgG levels were not different ([Figure S4](#mmc1){ref-type="supplementary-material"}E). IgM---but not IgG---levels to MDA-LDL and CuOx-LDL were also robustly and preferentially increased in recipient mice of *Siglec-G*^−/−^ bone marrow ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S4](#mmc1){ref-type="supplementary-material"}F--S4H). Importantly, total and B cell-selective deficiency of Siglec-G in the hematopoetic compartment resulted in a similar reduction of atherosclerotic lesion formation ([Figure 3](#fig3){ref-type="fig"}E) and a decreased lesional complexity with smaller necrotic areas and fewer lesional macrophages in the aortic root ([Figures 3](#fig3){ref-type="fig"}F--3H). This indicates that Siglec-G deficiency on B cells is primarily responsible for the protective effects in atherogenesis.

Siglec-G Deficiency in Mice Protects from Hepatic and Systemic Inflammation {#sec2.3}
---------------------------------------------------------------------------

We have recently demonstrated that *Ldlr*^−/−^ mice develop hepatic inflammation when fed an atherogenic diet ([@bib7]). Therefore, we investigated the effect of Siglec-G deficiency on hepatic inflammation in these mice. Atherogenic diet feeding resulted in a robust steatosis of the liver of all experimental mice. We found no significant differences in hepatic cholesterol, hepatic TG, and hepatic free fatty acids between the experimental groups. Consistent with only minimal liver damage in this model, alanine aminotransferase (ALT) levels were only moderately elevated, but also not different between the two groups ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). In contrast, immunohistochemical analyses of liver sections revealed a significantly reduced infiltration of Ly6G^+^ neutrophils and mac-1^+^ macrophages in the livers of *Ldlr*^−/−^*Siglec-G*^−/−^ mice compared to *Ldlr*^−/−^ mice ([Figures 4](#fig4){ref-type="fig"}A and 4B). A similar significant reduction in neutrophil and macrophage infiltration was found in the livers of *Ldlr*^−/−^ mice that were reconstituted with either *Siglec-G*^−/−^ or μMT+*Siglec-G*^−/−^ bone marrow ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). To further define the effects on hepatic inflammation between *Ldlr*^−/−^ and *Ldlr*^−/−^*Siglec-G*^−/−^ mice, we analyzed the expression of adhesion molecules, pro-inflammatory cytokines, and chemokines in the liver of these mice. In line with the reduced cell infiltration, expression of intercellular adhesion molecule (*Icam*) and vascular cell adhesion protein (*Vcam*), tumor necrosis factor-alpha (*Tnf-α*) and interleukin-18 (*Il-18*), C-C motif ligand 5 (*Ccl5*), C-X-C motif ligand 1 (*Cxcl1*), and C-X-C motif ligand 2 (*Cxcl2*) were significantly reduced in the livers of *Ldlr*^−/−^*Siglec-G*^−/−^ mice compared to *Ldlr*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}C). A similar though less pronounced decrease of inflammatory gene expression was also observed in the livers of mice lacking Siglec-G in B cells only ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Thus, Siglec-G deficiency and Siglec-G deficiency on B cells reduces hepatic inflammation, suggesting an important role in the development of steatohepatitis.

To assess systemic markers of inflammation in these mice, we quantified hepatic mRNA expression and the circulating levels of serum amyloid A (SAA), which in mice represents an acute phase protein that is induced during chronic inflammation ([@bib51]). Expression of *Saa1* was significantly reduced in the livers of *Ldlr*^−/−^*Siglec-G*^−/−^ mice compared to *Ldlr*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}C). Moreover, while plasma SAA levels increased after 8 weeks of atherogenic diet in *Ldlr*^−/−^, this was not the case for *Ldlr*^−/−^*Siglec-G*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}D). SAA levels in *Ldlr*^−/−^ mice that were reconstituted with μMT+*Siglec-G*^−/−^ or μMT+*wild-type* (*WT)* bone marrow after 10 weeks of atherogenic diet were lower in both groups, consistent with a more moderate degree of inflammation, but still showed a tendency toward reduced levels as a result of Siglec-G deficiency ([Figure S5](#mmc1){ref-type="supplementary-material"}D). To better characterize the inflammatory responses in these mice, we quantified the plasma levels of cytokines (TNF-α, IL-6, and IL-18) and chemokines (CCL2, CXCL1, and CXCL2) that have been previously identified to contribute to different pathogenic responses in atherosclerosis and hepatic inflammation ([@bib2], [@bib53]). Of all cytokines and chemokines tested, plasma levels of CXCL1 were significantly reduced both in *Ldlr*^−/−^*Siglec-G*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}E) and *Ldlr*^−/−^ mice lacking Siglec-G in B cells only compared to their respective controls ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Notably, Cxcl1 has been shown to be prominently induced in macrophages and endothelial cells stimulated with OxLDL and mediates the recruitment of neutrophils and monocytes ([@bib45], [@bib5]).

Thus, atherogenic diet is associated with increased inflammation in *Ldlr*^−/−^ mice, and this effect is suppressed in mice lacking Siglec-G. Collectively, these data point to a strong anti-inflammatory effect of Siglec-G deficiency in diet-induced hepatic and systemic inflammation.

Siglec-G Deficiency Protects from OxLDL-Induced Sterile Peritonitis {#sec2.4}
-------------------------------------------------------------------

Because we have previously shown that OSE-specific NAb inhibit pro-inflammatory effects of epitopes of OxLDL ([@bib50], [@bib26]), which is considered a major driver of vascular and hepatic inflammation ([@bib35], [@bib52]), we evaluated the effect of Siglec-G deficiency in an OxLDL-induced sterile inflammation model in vivo. For this, we first established a sterile peritonitis model that allowed us to monitor the recruitment of neutrophils and monocytes in the peritoneal lavage fluid (PLF) of WT C57BL/6 mice 2, 6, and 12 hr after they had received an intraperitoneal (i.p.) injection of OxLDL. Compared to baseline, mice injected with OxLDL exhibited a marked recruitment of Ly-6G^+^ neutrophils into the peritoneal cavity already after 2 hr, which remained significantly different, but gradually declined after 6 and 12 hr ([Figures 5](#fig5){ref-type="fig"}A, [S6](#mmc1){ref-type="supplementary-material"}, and [S7](#mmc1){ref-type="supplementary-material"}A). Similarly, peritoneal recruitment of Ly6C^+^CD11b^int^ inflammatory monocytes was also induced following i.p. injection of OxLDL, but only peaked 6 hr after the injection, consistent with the delayed recruitment of monocytes during inflammatory processes ([Figures 5](#fig5){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}A).

To investigate the anti-inflammatory effect of natural IgM associated with Siglec-G deficiency, we compared the dynamics of inflammatory cell recruitment during OxLDL-induced peritonitis in *Siglec-G*^*+/+*^ and *Siglec-G*^−/−^ mice, respectively. Consistent with the dramatic increase of IgM antibodies in the plasma of *Siglec-G*^−/−^ mice, we observed \>3-fold higher levels of total and \>9-fold higher levels of OxLDL-specific IgM in the PLF of *Siglec-G*^−/−^ mice at baseline ([Figures 5](#fig5){ref-type="fig"}C and 5D). At baseline, the numbers of peritoneal macrophages, which represent the cellular population that is primarily involved in responding to OxLDL, were not significantly different between *Siglec-G*^*+/+*^ and *Siglec-G*^−/−^ mice ([Figure S7](#mmc1){ref-type="supplementary-material"}C). *Siglec-G*^−/−^ mice showed a significantly reduced recruitment of neutrophils 2 hr after i.p. injection of OxLDL compared to *Siglec-G*^*+/+*^ mice, while after 6 hr, no differences between the two groups were observed ([Figure 5](#fig5){ref-type="fig"}E). Consistent with this, OxLDL-induced secretion of CXCL1 and CXCL2 was nearly absent in the peritoneal cavity of *Siglec-G*^−/−^ mice at this time point ([Figures 5](#fig5){ref-type="fig"}G and 5H). At 6 hours after i.p. injection of OxLDL, the recruitment of Ly-6C^+^CD11b^int^ inflammatory monocytes appeared lower in *Siglec-G*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}F). In contrast, Siglec-G deficiency had no effect on neutrophil recruitment in response to injection of thioglycollate (another sterile trigger), indicating that Siglec-G-deficient mice do not have defective inflammatory responses in general and demonstrating specificity for inflammatory responses triggered by OSE ([Figure S7](#mmc1){ref-type="supplementary-material"}D). In summary, Siglec-G deficiency results in a significant inhibition of the inflammatory response to OxLDL in vivo. The markedly reduced infiltration of neutrophils in *Siglec-G*^−/−^ mice in response to i.p. injection of OxLDL indicates direct neutralization of its pro-inflammatory moieties and more efficient clearance mediated by OSE-specific IgM.

Discussion {#sec3}
==========

In this study, we demonstrate a pathogenic role for Siglec-G in atherosclerosis and hepatic inflammation. We could show that Siglec-G deficiency in atherosclerosis-prone *Ldlr*^−/−^ mice leads to a marked reduction of atherosclerotic lesion burden as well as decreased hepatic inflammation. This effect is specific for Siglec-G deficiency in B cells that results in higher B-1 cell numbers and a robust and preferential increase in OSE-specific IgM antibodies, which neutralize OxLDL-induced inflammation in vivo.

Siglec-G is primarily expressed on B cells, with slightly higher expression levels on B-1a cells than on conventional B2 cells ([@bib22]), but it has also been shown to be expressed on dendritic cells and eosinophils ([@bib25], [@bib41]). A suppressive role of Siglec-G in non-B cells has been suggested in drug-induced liver damage, as Siglec-G deficiency results in increased production of pro-inflammatory cytokines, including IL-6, TNF-α, and MCP-1, following stimulation with DAMPs that are released in this setting ([@bib15]). Nevertheless, our data clearly identify an anti-inflammatory effect of Siglec-G deficiency in cholesterol-fed *Ldlr*^−/−^ mice as documented by reduced hepatic expression of adhesion molecules, pro-inflammatory cytokines, and chemokines as well as lower CXCL1 levels in plasma. Moreover, our data demonstrate Siglec-G deficiency to be protective in a model of OxLDL-induced peritonitis, while it has been shown to aggravate inflammation in cecal ligation and puncture-induced polybacterial peritonitis. These detrimental effects of Siglec-G deficiency have been shown to be dependent on its interaction with the glycosylphosphatidylinositol (GPI)-anchored co-stimulatory protein CD24 ([@bib16]). CD24 has been shown to recognize DAMPs and to allow Siglec-G to suppress pro-inflammatory signaling via pattern-recognition receptors, which can be disrupted by bacterial sialidases, but not by LPS. In our study, Siglec-G deficiency conferred a protective effect against another type of sterile trigger, OxLDL, as Siglec-G-deficient mice exhibited decreased inflammation in an OxLDL-induced peritonitis model. Presumably, the sterile inflammation induced by OxLDL also does not disrupt the interaction of CD24 and Siglec-G, suggesting that Siglec-G deficiency protects via other mechanisms than CD24.

It has also been shown that RNA viruses evade anti-viral defenses by upregulating Siglec-G in macrophages and dendritic cells, resulting in diminished production of type I interferons that are essential in the host defense against viruses ([@bib17]). As a consequence of this, Siglec-G deficiency results in increased production of type I interferons, which notably have been shown to promote atherosclerosis in several studies ([@bib2]). Because we have shown that Siglec-G deficiency protects from atherosclerosis, this pathway seems to be not relevant in this setting. In line with this, stimulation of peritoneal and bone-marrow derived macrophages with OxLDL does not induce Siglec-G expression (data not shown). Taken together, our data argue against a role of Siglec-G in myeloid cells with respect to atherosclerosis and hepatic inflammation. Moreover, we provide clear evidence that the protective effect of Siglec-G deficiency is mediated by B cells, indicating that the function of Siglec-G on B cells is dominant. In B cells, Siglec-G is expressed in all stages throughout B cell development ([@bib41], [@bib25]). Therefore, its functional role in autoimmunity has been studied, particularly in aging mice ([@bib36]). Old *Siglec-G*^−/−^ mice have been shown to exhibit an increased expression of activation markers on T cells and conventional B2 cells, suggesting a more general over-activation of the adaptive immune system in these settings. However, the effects described in our study are more consistent with the increased production of protective B-1 cell-derived NAb by Siglec-G-deficient mice. In line with previous data, we demonstrate that Siglec-G deficiency also resulted in a dramatic expansion of peritoneal B-1a as well as splenic B-1 cells in atherosclerotic mice. FO B cells and MZB cells remained unchanged in *Ldlr*^−/−^*Siglec-G*^−/−^ mice as well as in the bone marrow chimeric mice. Thus, our data support a protective role of B-1 cells in atherosclerosis ([@bib49]). Notably, we did observe a robust increase of the recently described IRA B cells in the spleens of atherosclerotic *Ldlr*^−/−^*Siglec-G*^−/−^ mice. These cells have been suggested to originate from B-1a cells and have been shown to promote atherosclerotic lesion formation ([@bib21]). Thus, although our data are in line with a B-1 cell origin of IRA B cells, the protective effects of B-1 cells dominate in atherosclerotic mice lacking Siglec-G. Previous studies demonstrated an atheroprotective effect of adoptive transfer of B-1a cells into splenectomized *Apoe*^−/−^ mice and of B-1b cells into *Rag-1*^−/−^*Apoe*^−/−^ mice ([@bib31], [@bib43]). These studies address the role of B-1 cells only in immune-compromised mice on top of existing differences in various immune cell populations, such as lack of splenocytes or total lymphocytes as a result of splenectomy or Rag-1 deficiency, respectively. However, they do not provide a conclusive answer on the role of B-1 cells in atherosclerosis in an intact host. Our data provide clear and direct genetic evidence that expansion of B-1a cells in intact mice mediates atheroprotection.

One of the major functions of B-1 cells is the secretion of natural IgM antibodies, which have been suggested to mediate the atheroprotective effect of B-1 cells. [@bib31] showed that accelerated lesion formation in splenectomized *Ldlr*^−/−^ mice, which exhibit diminished peritoneal B-1a cell numbers and reduced serum IgM, is reversed by the adoptive transfer of B-1a cells. This effect was dependent on the capacity of B-1a cells to secrete IgM, as adoptive transfer of B-1 cells from secreted *IgM*^−/−^ donors did not have any effect. The atheroprotective role of NAbs is further supported by the fact that *Ldlr*^−/−^ mice deficient in secreted IgM develop increased atherosclerosis compared to *Ldlr*^−/−^ control mice ([@bib32]). These data also suggested that increasing IgM titers above and beyond normal plasma levels could confer atheroprotection. Interestingly, hypercholesterolemia raises plasma IgM levels, presumably as part of an endogenous defense mechanism against increased accumulation of metabolic waste products ([@bib29]). However, this protective response is not sufficient to prevent the formation of atherosclerotic plaques and hepatic inflammation. Deficiency of Siglec-G results in an even greater increase of IgM antibodies despite excessive hypercholesterolemia, and thus Siglec-G may be an attractive target for therapeutic intervention, for example, by blocking antibodies.

Natural IgM exhibit house-keeping functions by promoting the clearance of dying cells and cellular debris ([@bib3], [@bib37]). These properties of natural IgM are in part mediated by their ability to recognize OSE, which are also present in OxLDL ([@bib35]). We have previously shown that immunization of high-fat diet-fed *Ldlr*^−/−^ mice with heat-killed pneumococci led to the expansion of a natural IgM clone recognizing OxLDL (T15/E06) and significantly decreased atherosclerotic lesion formation and hepatic inflammation ([@bib8], [@bib7]). These data suggested that anti-OxLDL IgM protect from atherosclerosis and liver inflammation. Indeed, epidemiological studies in humans indicate that high levels of OxLDL-specific IgM are associated with a lower incidence of cardiovascular disease ([@bib49]). Of note, Siglec-G deficiency, which results in atheroprotection, leads to a preferential increase of IgM with specificity for different epitopes of OxLDL in plasma.

Several mechanisms exist by which OxLDL-specific IgM exhibit atheroprotective properties, including their ability to inhibit foam cell formation by blocking scavenger receptor-mediated uptake of OxLDL by macrophages ([@bib49]). In addition, anti-OxLDL IgM prevent the accumulation of apoptotic cells by promoting their uptake by macrophages ([@bib38], [@bib18]). In line with this, we show smaller necrotic areas in lesion of *Ldlr*^−/−^*Siglec-G*^−/−^ mice. Moreover, anti-OxLDL IgM inhibit inflammation by components of OxLDL in vitro ([@bib26]). In agreement with a neutralizing effect of anti-OxLDL IgM, we now show reduced CXCL1 and CXCL2 secretion as well as neutrophil infiltration into the peritoneum in vivo following injection of OxLDL into *Siglec-G*^−/−^ mice, which have \>9-fold higher levels of anti-OxLDL IgM in the peritoneal cavity compared to WT controls. Moreover, plasma levels of CXCL1 were significantly reduced in Siglec-G-deficient atherosclerotic mice. OxLDL has been shown to induce Cxcl1 expression in macrophages via a co-operation of CD36/TLR4/TLR6, and CXCL1 represents a key mediator of leukocyte recruitment in atherosclerosis ([@bib45]). Moreover, both macrophage CD36 and TLR-4 expression have been shown to promote atherogenesis and hepatic inflammation. Thus, increased natural IgM with specificity for OxLDL have the capacity to inhibit atherosclerotic lesion formation and hepatic inflammation in Siglec-G-deficient mice by neutralizing the pro-inflammatory properties of OxLDL.

In conclusion, we provide evidence that expansion of natural IgM antibodies beyond physiological plasma levels protect from atherosclerosis and hepatic inflammation. Exploiting these mechanisms, for example, by blocking the inhibitory effect of Siglec-G, may represent a therapeutic approach to enhance and strengthen the endogenous defense mechanisms to protect from cardiovascular disease and associated metabolic disorders, such as non-alcoholic steatohepatitis.

Experimental Procedures {#sec4}
=======================

An expanded version of experimental procedures can be found in [Supplemental Information](#app2){ref-type="sec"}.

Animals and Intervention Studies {#sec4.1}
--------------------------------

All experimental protocols were approved by the institutional animal experimentation committee and the Austrian Ministry of Science. All mice were on a C57BL/6 background. *Ldlr*^−/−^ and *μMT* mice were purchased originally from The Jackson Laboratories (Bar Harbor, Maine, USA). The generation of C57BL/6 *Siglec-G*^−/−^ mice has been described elsewhere ([@bib36]). *Siglec-G*^−/−^ mice were further crossed with *Ldlr*^−/−^ mice to obtain *Ldlr*^−/−^*Siglec-G*^−/−^ and *Ldlr*^−/−^*Siglec-G*^*+/+*^ mice. For intervention studies, three cohorts of 12-week-old male *Ldlr*^−/−^*Siglec-G*^−/−^ mice (n = 14) and *Ldlr*^−/−^*Siglec-G*^*+/+*^ (n = 16) littermate controls were fed an atherogenic diet containing 21% milk fat and 0.2% cholesterol (TD88137, Ssniff Spezialdiäten) for 8 weeks. Bone marrow transplantation studies were performed as previously described ([@bib9], [@bib44], [@bib20]) and as described in [Supplemental Information](#app2){ref-type="sec"}.

Analysis of Atherosclerotic Lesions {#sec4.2}
-----------------------------------

The extent of atherosclerosis was assessed in a blinded fashion in *en face* preparations of the entire aorta and in cross-sections through the aortic origin by computer-assisted image analysis as previously described ([@bib8], [@bib9], [@bib11]).

Liver Histology {#sec4.3}
---------------

The left lobes of livers were harvested and four equal pieces were snap frozen in liquid nitrogen for further analyses. Frozen liver sections (7 μm) were stained for the presence of infiltrating macrophages and neutrophils as described previously ([@bib6]). For the presence of neutrophils, sections were stained with mouse anti-Ly6G (1:50; BD PharMingen). Cell nuclei were counterstained with hematoxylin (Klinipath). Pictures were taken with a Nikon digital camera DMX1200 and ACT-1 v2.63 software (Nikon). The number of positive-stained cells was counted in six pictures (200 ×) per liver per mouse to determine the level of liver inflammation.

Flow Cytometry {#sec4.4}
--------------

Peritoneal exudate cells (PEC), splenocytes, bone marrow cells, and blood leukocytes were harvested as previously described ([@bib11]) and stained as indicated in [Supplemental Information](#app2){ref-type="sec"}. Stained cell populations were analyzed by multiparameter flow cytometry using a BD FACSCalibur (BD Bioscience) or BD FACS Fortessa, respectively. Dead cells and doublets were excluded by forward- and side-scatter and data were analyzed using the FlowJo v10 data analysis software (Tree Star). Criteria used to identify the various cell populations are provided in [Table 1](#tbl1){ref-type="table"}.

Plasma Antibody and Protein Analyses {#sec4.5}
------------------------------------

Total IgM levels were measured by a chemiluminescent-based sandwich ELISA as described previously ([@bib18]). Total IgG levels were measured in plasma using a commercially available ELISA (Mouse IgG total ELISA Ready-SET-Go!, eBioscience). Cu^2+^-OxLDL (CuOx-LDL) and MDA-LDL were prepared as described previously ([@bib18]). α-1,3-dextran was a gift of John F. Kearney (University of Alabama at Birmingham, Alabama, USA). Antigen-specific antibody titers were measured by chemiluminescent ELISA as previously described ([@bib8]). OxLDL-specific IgM per total IgM ratios were calculated based on the measurements of specific IgM at non-saturating dilutions (expressed as RLU/100 ms) and total IgM quantities of each individual sample. Data are expressed as a.u. of these ratios. SAA levels were measured in plasma diluted 1:300 using a commercially available ELISA for mouse SAA (Tridelta Development).

Measurement of Chemokines/Cytokines in Plasma and PLF {#sec4.6}
-----------------------------------------------------

A panel of chemokines and cytokines (IL-6, TNF-α, CCXL1, CXCL2, CCL2, and IL-18) was measured in mouse plasma (1:2 dilution) with ProcartaPlex Multiplex Immunoassays (eBioscience) according to the manufacturer's protocol. Analysis was performed with the xMAP Technology by Luminex. Levels of CXCL1 and CXCL2 in the PLF were determined by using mouse CXCL1/KC DuoSet ELISA and Mouse CXCL2/MIP-2 DuoSet ELISA, respectively according to the manufacturer's protocol (R&D Systems).

Murine Sterile Peritonitis {#sec4.7}
--------------------------

*Siglec-G*^−/−^ mice and WT littermate controls (8--12 weeks of age) were injected i.p. with sterile CuOx-LDL (tested for endotoxin levels by chromogenic Limulus amoebocyte assay; \<0.05 ng LPS/mg protein) suspended in 600 μl of sterile PBS-BSA (25 μg/gram body weight) or a comparable volume of sterile thioglycollate (Lipid MAPS) (25 μl/g body weight). At selected time points, mice were sacrificed, and PEC were collected by lavaging the peritoneum with 6 ml of sterile PBS+1% BSA. PEC were pelleted for 10 min at 300 g, and processed for flow cytometry, as described above. Cell-free lavage fluid was stored in aliquots and further processed for ELISA measurements.

Statistical Analysis {#sec4.8}
--------------------

Data were analyzed using GraphPad Prism version 6.0 for Windows (GraphPad Software). Normal distribution of data was assessed, and statistical analyses were performed by unpaired Student's t-test to determine statistical significance between the groups. Data points, which were more than 2 × SD of the mean, were excluded as statistical outliers. Exclusion of these values did not change the significance of the results. Data are presented as the mean ± SEM and considered significant at p ≤ 0.05 (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001, respectively).
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![Siglec-G Deficiency in Cholesterol-Fed *Ldlr*^−*/*−^ Mice Increases B-1a Cell-Derived IgM Antibodies\
(A) Representative flow cytometry plots for splenic B220^+^CD43^−^ B2 cells and B220^+^CD43^+^ B-1 cell subpopulations. The parental gate was set on B220^+^IgM^+^ B cells.\
(B) Absolute numbers of splenic B220^+^IgM^+^CD43^+^ B-1 cells.\
(C) Representative flow cytometry plots for B cell subpopulations of the peritoneal cavity. The parental gate was set on B220^+^ B cells.\
(D) Relative numbers of peritoneal B220^+^CD5^+^CD11b^+^ B-1a cells out of total B cells.\
(E and F) Quantification of total IgM (E) and total IgG (F) antibodies in plasma. The samples were diluted between 1:30,000 and 1:70,000 and measured in triplicates.\
(G and H) Titers of MDA-LDL IgM (G) and CuOx-LDL IgM (H) in plasma were determined by ELISA at baseline and after 8 weeks of atherogenic diet. The samples were diluted between 1:100 and 1:500 and antibody binding was measured in triplicates. The data are expressed as relative light units (RLU) per 100 ms.\
(I) RLU of IgM antibodies to MDA-LDL and CuOx-LDL as well as α-1,3-dextran (1:100) were normalized to total IgM concentrations and expressed as ratio of specific IgM per total IgM (a.u.). Shown are data of *Ldlr*^−*/*−^ and *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ mice after 8 weeks of atherogenic diet. The symbols represent individual mice. The horizontal bars represent the mean of each group and errors bars represent SEM (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001).\
See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Siglec-G Deficiency Decreases Atherosclerosis in Cholesterol-Fed *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ Mice\
(A) Quantitative analysis of atherosclerosis in the aorta. The data are expressed as percentage of Sudan IV stained area of the entire aorta. The representative pictures are shown on the right.\
(B) Quantitative analysis of atherosclerotic lesions in cross-sections of innominate arteries. The values represent the average μm^2^ of four sections throughout the innominate artery (300 μm). The images show representative Masson's trichrome stains. The original magnification is 50×, and the scale bar represents 200 μm.\
(C) Quantification of atherosclerotic lesion size in cross-sections at the aortic origin. The values represent the average μm^2^ of nine sections throughout the entire aortic origin (400 μm). The images show representative Masson's trichrome stains. The original magnification is 50Χ, and the scale bar represents 200 μm.\
(D) Quantification of necrotic areas in cross-sections at the aortic origin. The values represent the percentages of necrotic areas of one section at 200 μm depth.\
(E--G) Quantification of macrophage, collagen, and IgM content in cross-sections at the aortic origin.\
(E) Values represent the percentage of mac-3^+^ area per cellular lesion area of one section per mouse at 200 μm depth.\
(F) Values represent the percentage of Sirius Red^+^ area per total lesion area of one section per mouse at 200 μm depth.\
(G) Values represent the percentage of IgM^+^ area per cellular lesion area of one section per mouse at 180 μm depth. Shown are the data of *Ldlr*^−*/*−^ and *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ mice after 8 weeks of atherogenic diet. The symbols represent individual mice. The horizontal bars represent the mean of each group and errors bars represent SEM (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001).\
See also [Table 1](#tbl1){ref-type="table"}.](gr2){#fig2}

![Selective Siglec-G Deficiency in B Cells Reduces the Development of Atherosclerosis\
(A) Absolute numbers of splenic IgM^+^B220^+^CD43^+^ B-1 cells.\
(B) Quantification of total IgM in plasma. The samples were diluted 1:60,000 and measured in triplicates.\
(C and D) Binding of IgM antibodies to (C) MDA-LDL and (D) CuOx-LDL was determined by ELISA. The plasma samples were diluted between 1:100 and 1:500 and antibody binding was measured in triplicates. The data are expressed as RLU/100 ms.\
(E) Quantitative analysis of atherosclerosis (*en face*) in the entire aorta. The data are expressed as percentage of Sudan IV stained area of the entire aorta.\
(F) Quantification of atherosclerotic lesion size in cross-sections at the aortic origin. The values represent the average μm^2^ of nine sections throughout the entire aortic origin (400 μm).\
(G) Quantification of necrotic areas in cross-sections at the aortic origin. The values represent percentages of necrotic areas of one section at 200 μm.\
(H) Quantification of the macrophage content in cross-sections at the aortic origin. The values represent percentages of mac-3^+^ area per total lesion area of one section per mouse at 200 μm depth. Shown are data of *Ldlr*^−*/*−^ mice reconstituted with *Siglec-G*^*+/+*^ \[WT\] versus *Siglec-G*^−*/*−^ \[KO\] and μMT+*Siglec-G*^*+/+*^ \[WT\] versus μMT+*Siglec-G*^−*/*−^ \[KO\] bone marrow after 10 weeks of atherogenic diet. The symbols represent individual mice. The horizontal bars represent the mean of each group and errors bars represent SEM (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.00).\
See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}; [Table 2](#tbl2){ref-type="table"}.](gr3){#fig3}

![Siglec-G Deficiency Protects from Atherogenic Diet-Induced Hepatic and Systemic Inflammation\
(A and B) Quantification of infiltrating neutrophils (A) and macrophages (B) in liver sections of *Ldlr*^−*/*−^ versus *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ mice after 8 weeks of atherogenic diet. The sections were stained with anti-Ly6G and anti-mac-1 antibody. The positively stained cells were counted and expressed as number of positive cells per mm^2^. The representative pictures (original magnification 200× and the scale bar represents 100 μm) are shown on the right.\
(C) Relative gene expression of *Icam, Vcam, Tnf-α, Il-18, Ccl5, Cxcl1, Cxcl2*, and *Saa1* mRNA in livers of *Ldlr*^−*/*−^ versus *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ mice after 8 weeks of atherogenic diet. The expression data of individual genes was normalized to the house-keeping gene S12 and expressed relative to the expression in *Ldlr*^−*/*−^ control mice.\
(D) Quantification of SAA levels in plasma of *Ldlr*^−*/*−^ versus *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ mice at baseline and after 8 weeks of atherogenic diet. The samples were diluted 1:300 and measured in triplicates.\
(E) Quantification of TNFα, IL-6, IL-18, CCL2, CXCL1, and CXCL2 in plasma of *Ldlr*^−*/*−^ versus *Ldlr*^−*/*−^*Siglec-G*^−*/*−^ mice after 8 weeks of atherogenic diet by multiplex assay. The samples were diluted 1:2. The data represent mean ± SEM of 9--13 mice per group (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001).\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![OxLDL-Induced Sterile Peritonitis Is Suppressed by Siglec-G Deficiency\
(A and B) Quantification of absolute numbers of Ly6G^+^ neutrophils (A) and Ly6C^hi^ inflammatory monocytes (B) in the PLF of C57BL/6 mice at baseline, as well as 2, 6, and 12 hr after OxLDL injections.\
(C) Quantification of total IgM in the PLF of *Siglec-G*^*+/+*^ and *Siglec-G*^−*/*−^ mice. The samples were diluted 1:20 and measured in triplicates.\
(D) Binding of IgM to CuOx-LDL in the PLF of *Siglec-G*^*+/+*^ and *Siglec-G*^−*/*−^ mice was determined by ELISA. The samples were undiluted and antibody binding was measured in triplicates. The data are expressed as relative RLU/100 ms.\
(E and F) Quantification of absolute numbers of Ly6G^+^ neutrophils (E) and Ly6C^hi^ monocytes (F) in the PLF of *Siglec-G*^*+/+*^ and *Siglec-G*^−*/*−^ mice at baseline, 2, and 6 hr after i.p. injection of OxLDL.\
(G and H) Quantification of CXCL1 (G) and CXCL2 (H) in the PLF of *Siglec-G*^*+/+*^ and *Siglec-G*^−*/*−^ mice at indicated time points by ELISA. The samples were undiluted and measured in duplicates. The data represent mean ± SEM of 3--7 mice per group and are a representative example of three individual experiments (^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, and ^∗∗∗^p ≤ 0.001). See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

###### 

Parameters Overview of Experimental Groups: Atherosclerosis Study

                                                                       *Ldlr*^−*/*−^      *Ldlr*^−*/*−^*Siglec-G*^−*/*−^
  -------------------------------------------------------------------- ------------------ --------------------------------
  **Metabolic Parameters**[a](#tblfn1){ref-type="table-fn"}                               
  Weights (g)                                                          32.15 ± 0.53       31.2 ± 0.90
  TC (mg/dL)                                                           1,655.36 ± 70.24   1,633.65 ± 88.09
  TG (mg/dL)                                                           1,257.14 ± 55.37   1,284.38 ± 61.18
  **Atherosclerosis**                                                                     
  *en face* (% of aorta)                                               4.22 ± 0.25        2.22 ± 0.20^∗∗∗^
  Innominate (× 10^4^ mm^2^)                                           0.99 ± 0.17        0.43 ± 0.16^∗^
  Aortic origin (× 10^4^ μm^2^/section)                                7.08 ± 0.88        8.69 ± 1.14
  Necrotic area (% of total lesion area)                               14.8 ± 4.0         4.65 ± 1.21^∗^
  mac-3^+^ (% of cellular area)                                        65.83 ± 3.78       51.61 ± 2.53^∗∗^
  **Hepatic Inflammation**                                                                
  Liver cholesterol (μg TC/μg protein)                                 0.19 ± 0.01        0.19 ± 0.02
  Liver TG (μg TG/μg protein)                                          0.68 ± 0.04        0.62 ± 0.06
  Liver free fatty acids (μg FFA/μg protein)                           0.42 ± 0.02        0.37 ± 0.04
  ALT (U/l)                                                            72.9 ± 8.1         80.4 ± 6.6
  Mac-1 (\# positive cells/mm^2^)                                      150.04 ± 6.74      118.58 ± 6.14^∗∗^
  Ly6G (\# positive cells/mm^2^)                                       68.38 ± 2.61       55.91 ± 2.32^∗∗^
  **Serum Antibody Titers**                                                               
  Total IgM (mg/ml)                                                                       
  Baseline                                                             0.26 ± 0.05        1.15 ± 0.05^∗∗∗^
  8 weeks HFD                                                          0.87 ± 0.06        1.36 ± 0.06^∗∗∗^
  MDA-LDL IgM (RLU/100 ms)                                                                
  Baseline                                                             30,735 ± 1,534     54,680 ± 2,101^∗∗∗^
  8 weeks HFD                                                          54,378 ± 2,196     80,773 ± 2,467^∗∗∗^
  CuOx-LDL IgM (RLU/100 ms)                                                               
  Baseline                                                             3,767 ± 585        12,459 ± 1,894^∗∗∗^
  8 weeks HFD                                                          19,549 ± 2,443     40,649 ± 2,698^∗∗∗^
  Total IgG (mg/ml)                                                                       
  Baseline                                                             0.24 ± 0.02        0.39 ± 0.07
  8 weeks HFD                                                          0.72 ± 0.06        0.89 ± 0.07
  MDA-LDL IgG (RLU/100 ms)                                                                
  Baseline                                                             14,879 ± 1,855     22,392 ± 2,383^∗^
  8 weeks HFD                                                          20,646 ± 1,800     23,699 ±1,870
  CuOx-LDL IgG (RLU/100 ms)                                                               
  Baseline                                                             1,473 ± 91         3,220 ± 525^∗∗^
  8 weeks HFD                                                          3,267 ± 356        4,463 ± 449
  **Spleen (Absolute Numbers × 10^6^)**                                                   
  T cells (CD3^+^)                                                     34.18 ± 2.30       37.97 ± 3.04
  B cells (B220^+^IgM^+^)                                              33.14 ± 2.44       38.64 ± 4.25
  B-1 cells (B220^+^IgM^+^CD43^+^)                                     2.63 ± 0.32        5.56 ± 0.73^∗∗∗^
  MZ B cells (B220^+^CD43^−^CD23^−^CD21^hi^)                           0.71 ± 0.11        0.54 ± 0.09
  T2/FO B cells (B220^+^CD43^−^CD23^+^CD21^+^)                         26.87 ± 2.26       34.0 ± 3.71
  T1 B cells (B220^+^CD43^−^CD23^−^CD21^lo^)                           1.96 ± 0.18        2.71 ± 0.36
  B220^+^CD43^−^ CD23^−^ CD21^+^                                       1.50 ± 0.15        1.84 ± 0.15
  IRA B cells (CD19^+^IgM^high^CD43^+^CD5^+^CD138^+^CD93^+^MHCII^+^)   0.09 ± 0.01        0.18 ± 0.03^∗∗^
  **Peritoneal Cavity (% Viable Cells)**                                                  
  B-1a cells (B220^+^CD11b^+^CD5^+^) out of B cells                    27.74 ± 1.59       37.78 ± 2.60^∗∗^
  B-1b cells (B220^+^CD11b^+^CD5^−^) out of B cells                    15.57 ± 1.46       12.39 ± 1.41
  B2 cells (B220^+^CD11b^−^CD5^−^) out of B cells                      35.29 ± 1.84       33.2 ± 1.84
  T cells (B220^−^CD5^+^) out of total                                 8.99 ± 1.10        9.42 ± 0.86

See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Data are shown as mean ± SEM (^∗^ p ≤ 0.05, ^∗∗^ p ≤ 0.01, and ^∗∗∗^ p ≤ 0.001).

###### 

Parameters Overview of Experimental Groups: Bone Marrow Transplantation Study

  *Ldlr*^−*/*−^*←*                                            C57BL/6          *Siglec-G*^−*/*−^     *μMT*+C57BL/6    *μMT+Siglec-G*^−*/*−^
  ----------------------------------------------------------- ---------------- --------------------- ---------------- -----------------------
  **Metabolic Parameters**[a](#tblfn2){ref-type="table-fn"}                                                           
  Weights (g)                                                 25.54 ± 0.63     25.15 ± 0.67          25.72 ± 0.49     25.29 ± 0.73
  TC (mg/dL)                                                  758.33 ± 79.47   821.59 ± 66.53        884.67 ± 92.20   925.96 ± 78.29
  TG (mg/dL)                                                  595.83 ± 49.43   567.05 ± 48.57        661.46 ± 73.94   585.58 ± 46.60
  **Atherosclerosis**                                                                                                 
  *en face* (% of aorta)                                      3.04 ± 0.38      0.59 ± 0.15^∗∗∗^      3.11 ± 0.24      1.17 ± 0.34^∗∗∗^
  Aortic origin (× 10^4^ μm^2^/section)                                                              4.84 ± 1.14      4.03 ± 1.13
  Necrotic area (% of total lesion area)                                                             5.20 ± 1.48      1.09 ± 0.66^∗^
  mac-3^+^ (% of total area)                                                                         54.96 ± 6.57     38.60 ± 4.95^∗^
  **Hepatic Inflammation**                                                                                            
  Liver cholesterol (μg TC/μg protein)                        0.22 ± 0.04      0.19 ± 0.03           0.23 ± 0.03      0.23 ± 0.03
  Liver TG (μg TG/μg protein)                                 0.25 ± 0.04      0.21 ± 0.02           0.25 ± 0.03      0.22 ± 0.02
  Liver free fatty acids (μg FFA/μg protein)                  0.14 ± 0.01      0.12 ± 0.01           0.15 ± 0.01      0.15 ± 0.01
  ALT (U/l)                                                   109.1 ± 27.2     58.8 ± 11.5           47.6 ± 4.8       38.6 ± 3.0
  Mac-1 (\# positive cells/mm^2^)                             120.69 ± 13.08   86.72 ± 8.95^∗^       100.68 ± 6.33    79.41 ± 5.50^∗^
  Ly6G (\# positive cells/mm^2^)                              79.67 ± 5.82     58.58 ± 7.41^∗^       74.40 ± 6.30     48.61 ± 4.04^∗∗^
  **Serum Antibody Titers---10 Weeks HFD**                                                                            
  Total IgM (mg/ml)                                           0.47 ± 0.10      0.92 ± 0.11^∗∗^       0.55 ± 0.10      1.07 ± 0.10^∗∗∗^
  MDA-LDL IgM (RLU/100ms)                                     23,939 ± 2,848   32,989 ± 1,848^∗∗^    23,514 ± 1,706   30,045 ± 943^∗∗^
  CuOx-LDL IgM (RLU/100ms)                                    4,877 ± 951      12,566 ± 1,583^∗∗∗^   5,714 ± 829      11,704 ± 1,045^∗∗∗^
  Total IgG (mg/ml)                                           0.47 ± 0.10      0.89 ± 0.10^∗^        0.61 ± 0.09      0.98 ± 0.27
  MDA-LDL IgG (RLU/100ms)                                     3,220 ± 633      6,126 ± 1,248         4,405 ± 701      4,012 ± 752
  CuOx-LDL IgG (RLU/100ms)                                    2,885 ± 754      3,476 ± 769           1,827 ± 274      1,990 ± 452
  **Spleen (Absolute Numbers × 10^6^)**                                                                               
  T cells (CD3^+^)                                            41.93 ± 4.76     37.51 ± 3.86          67.76 ± 17.05    42.90 ± 8.13
  B cells (B220^+^IgM^+^)                                     66.80 ± 9.44     74.18 ± 9.22          43.85 ± 12.07    47.46 ± 13.18
  B1 cells (B220^+^IgM^+^CD43^+^)                             3.21 ± 0.38      6.15 ± 0.75^∗∗^       2.82 ± 0.60      6.04 ± 1.32^∗∗^
  MZ B cells (B220^+^CD43^−^CD23^−^CD21^hi^)                  1.98 ± 0.35      1.56 ± 0.26           4.58 ± 1.41      2.94 ± 1.28
  T2/FO B cells (B220^+^CD43^−^CD23^+^CD21^+^)                46.04 ± 5.43     54.25 ± 7.49          23.47 ± 7.63     25.28 ± 8.42
  T1 B cells (B220^+^CD43^−^CD23^−^CD21^lo^)                  3.42 ± 0.77      3.46 ± 0.35           3.68 ± 2.40      2.24 ± 0.72
  B220^+^CD43^−^ CD23^−^ CD21^+^                              5.99 ± 1.18      5.48 ± 0.67           4.16 ± 1.05      5.38 ± 2.08
  **Peritoneal Cavity (% Viable Cells)**                                                                              
  B-1a cells (B220^+^CD11b^+^CD5^+^) out of B cells           17.13 ± 1.40     31.85 ± 1.14^∗∗∗^     25.18 ± 0.62     46.20 ± 1.07^∗∗∗^
  B-1b cells (B220^+^CD11b^+^CD5^−^) out of B cells           14.17 ± 1.24     12.47 ± 0.97          19.45 ± 1.29     15.96 ± 0.83^∗^
  B2 cells (B220^+^CD11b^−^CD5^−^) out of B cells             64.96 ± 2.32     48.47 ± 2.00^∗∗∗^     47.40 ± 1.94     29.88 ± 1.06^∗∗∗^
  T cells (B220^−^CD5^+^) out of total                        11.99 ± 1.19     15.07 ± 2.68          18.18 ± 5.04     13.97 ± 2.89

Data are shown as mean ± SEM (^∗^ p ≤ 0.05, ^∗∗^ p ≤ 0.01, and ^∗∗∗^ p ≤ 0.001).
